Here is Why Opus Genetics (IRD) is One of the Best Performing NASDAQ Stocks

Opus Genetics Inc. (NASDAQ:IRD) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 6, Opus Genetics secured a financing agreement with Oberland Capital, providing up to $155 million in non-dilutive funding and a $5 million equity investment. This capital infusion, combined with current resources, extends the company’s cash runway into 2029. The funding is designated to support the completion of pivotal studies for OPGx-LCA5 and OPGx-BEST1, initiate pre-launch commercial activities, and advance earlier-stage pipeline programs into clinical testing.

The agreement includes an upfront payment of $35 million in notes and a concurrent purchase of 1.1 million shares of common stock at $4.48 per share. Opus Genetics can access additional tranches of funding over the next 2 years based on clinical milestones, including the potential regulatory approval of its LCA5 program. The notes carry a 7-year maturity with a 6-year interest-only period, providing the financial flexibility to leverage the company’s gene therapy platform while maintaining a focus on inherited retinal diseases/IRDs.

With a strengthened balance sheet, Opus Genetics Inc. (NASDAQ:IRD) plans to transition three additional programs into the clinic over the next year: OPGx-RDH12, OPGx-MERTK, and OPGx-RHO. These programs target rare conditions that cause blindness and affect tens of thousands of patients globally. The company remains on track to report topline results from its Phase 1/2 trial of OPGx-BEST1 in mid-2026, marking a critical step toward restoring vision for patients with limited treatment options.

Opus Genetics Inc. (NASDAQ:IRD) is involved in the research and development of ophthalmic biopharmaceutical products, with a focus on the development and commercialization of therapies for the treatment of several eye disorders.

While we acknowledge the potential of IRD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.